Skip to content
Loading...
SynAct Pharma logo
  • About
    • Management
    • Board of Directors
    • Advisory Board
    • History
    • Governance
      • General Meetings
      • Governance reports
      • Board Committees
      • Nomination Committee
      • Articles of Association
      • Auditor
    • Code of Conduct
    • Career
  • Our Science
    • Focus Areas
      • Autoimmune and Inflammatory Diseases
      • Host-Directed Therapy – Viral Infections
    • Our Medicines
      • Oral Drugs
      • Peptides
    • Synact Wiki
  • Diseases
    • Rheumatoid Arthritis
    • Nephrotic Syndrome
    • Polymyalgia Rheumatica
    • Dengue Fever
    • COVID-19
  • Development Program
    • Resomelagon
      • Inflammatory and Autoimmune Diseases
        • RA: The BEGIN Study
        • RA: The EXPAND Study
        • RA: The RESOLVE Study
        • RA: The ADVANCE Study
        • iMN: SynAct-CS003
      • Host-Directed Therapy in Viral Infections
        • COVID-19: RESOVIR-1
        • Dengue Fever: RESOVIR-2
    • TXP-11
  • Investors
    • Message from the CEO
    • Investment Highlights
    • Financial Reports
    • The Share
      • Share capital
    • Ownership Structure
    • Board and Management Holdings
    • Analysts
    • Presentations
    • Calendar
    • Prospectus and Rights Issues
  • News & Media
    • News and Press Releases
    • SynAct in the Media
    • Slide Decks and Presentations
    • Image Bank
  • ENG
  • SVE

General Meetings

Hero image
November 27, 2025

Extraordinary General Meeting November 2025

27 May, 2025

Annual General Meeting 2025

December 13, 2024

Extraordinary General Meeting December 2024

May 31, 2024

Annual General Meeting 2024

April 24, 2024

Extraordinary General Meeting April 2024

March 20, 2024

Extraordinary General Meeting March 2024

May 25, 2023

Annual General Meeting 2023

January 12, 2023

Extraordinary General Meeting January 2023

May 20, 2022

Annual General Meeting 2022

March 28, 2022

Extraordinary General Meeting March 2022

May 21, 2021

Annual General Meeting 2021

November 6, 2020

Extraordinary General Meeting November 2020

November 6, 2020

Extraordinary General Meeting 2020

8 november, 2019

Extra bolagsstämma 2019

May 21, 2021

Årsstämma 2019

21 mars, 2019

Extra bolagsstämma 2019

15 maj, 2018

Årsstämma 2018

10 april, 2018

Extra bolagsstämma 2018

About
  • Management
  • Board of Directors
  • Advisory Board
  • History
  • Governance
    • General Meetings
    • Governance reports
    • Board Committees
    • Nomination Committee
    • Articles of Association
    • Auditor
  • Code of Conduct
  • Career

SynactPharma-white

Advancing medicine trough
melanocortin activation

SynAct Pharma AB (publ)
Scheelevägen 2
SE-223 63 Lund
Sweden

Synact Pharma ApS
Dronninggårds Alle 136
2840 Holte
Denmark

  • About
  • Our Science
  • Diseases
  • Development Program
  • Investors
  • News & Media
  • Privacy Policy
  • Cookies
  • Get the latest news follow us on Linkedin

© 2025 SynAct Pharma AB. All right reserved.